Semaglutide for Weight Loss: Evidence, Safety and Common Questions

How semaglutide supports weight loss

Semaglutide mimics the hormone GLP‑1, acting on appetite and satiety centres in the brain and gut. People typically notice:

• reduced hunger and fewer cravings
• feeling full sooner and for longer
• smaller portions without feeling deprived
• slower stomach emptying, which can also reduce snacking

It is not a stimulant and does not “melt fat.” It helps you consistently eat less so a calorie deficit is easier to sustain alongside a nutrition and activity plan.

Get GLP‑1 guidance

Expected results and timelines

In the STEP clinical trials, adults using semaglutide 2.4 mg weekly (Wegovy) with lifestyle support lost on average around 15% of their starting weight over 68 weeks. Many achieved 10–20% reductions. People with type 2 diabetes tend to see somewhat lower averages than those without diabetes.

Typical pattern:

• Weeks 2–4: appetite starts to drop during dose escalation
• Weeks 4–12: measurable weight change in most people
• 3–6 months: larger, more visible reductions
• 12–18 months: plateau and maintenance with the approved dose and ongoing lifestyle support

Results vary by dose tolerance, adherence, nutrition, activity, sleep, medications and medical history.

For a deeper breakdown, see Semaglutide Results Timeline.

Map your likely timeline

Dosing and titration for weight loss

To reduce side effects, prescribers usually increase the dose gradually. A common Wegovy schedule is:

• 0.25 mg weekly for 4 weeks
• 0.5 mg weekly for 4 weeks
• 1.0 mg weekly for 4 weeks
• 1.7 mg weekly for 4 weeks
• 2.4 mg weekly ongoing as maintenance (if tolerated)

Ozempic pens have different strengths and are approved for diabetes. Any weight‑loss use is off‑label and should follow an agreed plan with your clinician.

Practical tips discussed with clinicians include injection technique, rotating sites, eating slowly, prioritising protein, and pausing dose escalations if nausea is significant.

Learn more in the Semaglutide Dosage Guide and Ozempic vs Wegovy.

Discuss a titration plan

Safety, side effects and when to seek help

Common effects are gastrointestinal and usually improve as your body adapts:

• nausea, vomiting, reflux/heartburn
• diarrhoea or constipation
• bloating, stomach discomfort, early fullness

Less common but important:

• gallbladder issues (e.g., gallstones)
• pancreatitis (seek urgent care for severe, persistent upper abdominal pain with or without vomiting)
• possible bowel obstruction or severe dehydration from ongoing vomiting/diarrhoea
• low blood sugar if used with insulin or some sulfonylureas

Not suitable for: pregnancy or breastfeeding; personal/family history of medullary thyroid carcinoma or MEN2; a history of pancreatitis; certain severe GI diseases; and other specific conditions your doctor will review.

See the detailed Semaglutide Side Effects Guide and Ozempic Side Effects.

Ask about safety in your case

Who may be eligible in Australia

Prescribers typically consider semaglutide for adults who meet one of the following:

• BMI ≥30, or
• BMI ≥27 with weight‑related health risks (e.g., prediabetes, T2D, dyslipidaemia, hypertension, obstructive sleep apnoea).

Approval and brand selection differ by indication:

• Wegovy is TGA‑approved for chronic weight management in eligible adults.
• Ozempic is TGA‑approved for type 2 diabetes; weight‑loss use is off‑label and requires clinical justification.

Financing and availability differ too: Wegovy for weight loss is not PBS‑subsidised. Ozempic is PBS‑listed for diabetes only. Supply can fluctuate, so your prescriber and pharmacy will advise on current access.

Related reads: Semaglutide Prescription Australia, Semaglutide Cost Australia, Is Semaglutide Legal in Australia?

Check eligibility with a clinic

Brands and access in Australia

• Wegovy (semaglutide 2.4 mg weekly): weight‑management indication.
• Ozempic (semaglutide 0.25–2.0 mg weekly): type 2 diabetes indication; weight loss use is off‑label.
• Rybelsus (oral semaglutide): type 2 diabetes indication; not a weight‑management brand.

Be cautious with compounded semaglutide or “research” products promoted online. Compounded versions are not TGA‑approved; quality, strength and sterility can vary. Discuss legal access and safer routes with a qualified prescriber.

See: Buy Semaglutide Australia, Weight Loss Injections Australia, GLP‑1 Australia Guide.

Find a legitimate provider

Making results stick: food, training and follow‑up

• Prioritise protein (e.g., 1.2–1.6 g/kg/day as advised) to support lean mass while losing weight.
• Resistance training 2–3 times weekly helps preserve muscle and resting energy expenditure.
• Sleep 7–9 hours and manage stress—both influence appetite and cravings.
• Limit alcohol (extra calories; may worsen reflux and nausea).
• Plan a maintenance strategy with your clinician. Some need long‑term therapy or a lower “maintenance” dose; stopping abruptly often leads to weight regain.

Build a maintenance plan

Alternatives and comparisons

• Semaglutide vs Tirzepatide Weight Loss (tirzepatide is a dual GIP/GLP‑1 agonist).
• Liraglutide vs Semaglutide (daily vs weekly GLP‑1s).
• Ozempic vs Wegovy and Rybelsus vs Ozempic.
• Mounjaro (Tirzepatide) Australia Guide and Tirzepatide for Weight Loss.

Compare options with a clinician

Frequently asked questions

Have another question? Ask now

Key takeaway

Semaglutide can meaningfully reduce body weight by helping you feel satisfied on less food. Results are strongest when paired with structured nutrition, resistance training and regular clinical follow‑up. Safety and access vary, so personalised assessment is essential.

Start your assessment